Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 12/20 | 0.74 |
| ▸ | ROCK1 known ✓ | Q13464 | 12/20 | 0.74 |
| ▸ | PRKCD known ✓ | Q05655 | 4/20 | 0.59 |
| ▸ | PRKD3 known ✓ | O94806 | 3/20 | 0.59 |
| ▸ | PRKCZ known ✓ | Q05513 | 3/20 | 0.59 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.59 |
| ▸ | FGFR1 known ✓ | P11362 | 1/20 | 0.59 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.59 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.59 |
| ▸ | MMP1 known ✓ | P03956 | 2/20 | 0.41 |
| ▸ | MMP13 known ✓ | P45452 | 2/20 | 0.41 |
| ▸ | PRKCG known ✓ | P05129 | 2/20 | 0.39 |
| ▸ | PRKCB known ✓ | P05771 | 2/20 | 0.39 |
| ▸ | PRKCA known ✓ | P17252 | 2/20 | 0.39 |
| ▸ | PRKCH known ✓ | P24723 | 2/20 | 0.39 |
| ▸ | PRKCI known ✓ | P41743 | 2/20 | 0.39 |
| ▸ | PRKCE known ✓ | Q02156 | 2/20 | 0.39 |
| ▸ | PRKCQ known ✓ | Q04759 | 2/20 | 0.39 |
| ▸ | PRKD1 known ✓ | Q15139 | 2/20 | 0.39 |
| ▸ | PRKACA | P17612 | 4/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1811642 | 1.00 | ROCK2 (0.74) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| SCHEMBL678400 | 0.99 | ROCK2 (0.75) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| SCHEMBL30168969 | 0.99 | ROCK2 (0.75) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| SCHEMBL4553608 | 0.99 | ROCK2 (0.75) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| Hydrochloric Acid SCHEMBL4897166 | 0.91 | ROCK2 (0.66) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| Hydrochloric Acid SCHEMBL4897175 | 0.91 | ROCK2 (0.66) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| SCHEMBL13951383 | 0.90 | ROCK2 (0.62) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| SCHEMBL13606963 | 0.90 | ROCK2 (0.62) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| SCHEMBL13606925 | 0.90 | ROCK2 (0.67) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| SCHEMBL13606964 | 0.88 | ROCK2 (0.60) | ROCK2ROCK1PRKACAPRKCDPRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2494035-B1 | PLURIPOTENT STEM CELLS | JANSSEN BIOTECH INC (US) | 2018-02-28 | — | — | EP | claimed |
| EP-4747356-A1 | CO-CULTURES OF ORGANOIDS AND STROMAL CELLS | HUB Organoids IP B.V. (NL) | 2026-05-27 | — | — | EP | disclosed |
| US-12618830-B2 | Methods, culture medias and devices for generating embryos in vitro from stem cells | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2026-05-05 | — | — | US | disclosed |
| EP-4709477-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF MICROVASCULATURE DYSFUNCTION AND RELATED DISEASES | The Texas A&M University System (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260062678-A1 | CELL REPLACEMENT THERAPY FOR PULMONARY DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260014139-A1 | Femtosecond Laser Treatment Methods | PEYMAN GHOLAM A (US) | 2026-01-15 | — | — | US | disclosed |
| US-12467917-B2 | Reconstructing human early embryogenesis in vitro with pluripotent stem cells | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2025-11-11 | — | — | US | disclosed |
| US-12396889-B2 | Lamellar corneal autologous or homologous graft in refractive surgery | PEYMAN GHOLAM A (US) | 2025-08-26 | — | — | US | disclosed |
| EP-4581130-A1 | METHODS AND CULTURE MEDIA FOR GENERATING EMBRYOS IN VITRO FROM PLURIPOTENT STEM CELLS | California Institute of Technology (US) | 2025-07-09 | — | — | EP | disclosed |
| EP-4581131-A1 | DIFFERENTIAL ADHESION AND TENSION GUIDED FORMATION OF STEM CELL DERIVED EMBRYOS | California Institute of Technology (US) | 2025-07-09 | — | — | EP | disclosed |
| EP-2366021-B1 | PLURIPOTENT STEM CELL CULTURE ON MICRO-CARRIERS | JANSSEN BIOTECH INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20160177269-A1 | METHODS FOR GENERATING STEM CELL-DERIVED BETA CELLS AND METHODS OF USE THEREOF | HOWARD HUGHES MEDICAL INSTITUTE | 2016-06-23 | — | — | US | disclosed |
| US-20160177267-A1 | SERUM-FREE IN VITRO DIRECTED DIFFERENTIATION PROTOCOL FOR GENERATING STEM CELL-DERIVED BETA CELLS AND USES THEREOF | HOWARD HUGHES MEDICAL INSTITUTE | 2016-06-23 | — | — | US | disclosed |
| US-20150166950-A1 | Pluripotent Stem Cell Culture on Micro-Carriers | JANSSEN BIOTECH, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| EP-2494035-A2 | PLURIPOTENT STEM CELLS | Janssen Biotech, Inc. (US) | 2012-09-05 | — | — | EP | disclosed |
| EP-2366021-A1 | PLURIPOTENT STEM CELL CULTURE ON MICRO-CARRIERS | Centocor Ortho Biotech Inc. (US) | 2011-09-21 | — | — | EP | disclosed |
| WO-2011059725-A2 | PLURIPOTENT STEM CELLS | CENTOCOR ORTHO BIOTECH INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20110104805-A1 | Pluripotent Stem Cells | CENTOCOR ORTHO BIOTECH INC. (US) | 2011-05-05 | — | — | US | disclosed |
| WO-2010059775-A1 | PLURIPOTENT STEM CELL CULTURE ON MICRO-CARRIERS | CENTOCOR ORTHO BIOTECH INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| US-20100124781-A1 | Pluripotent Stem Cell Culture on Micro-Carriers | NELSON SHELLEY | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014139-A1 | Femtosecond Laser Treatment Methods | GSK3B, GSK3A, CTNND1 | ROCK2 17/4885ROCK1 13/4885PRKCD 14/4885 |
| US-20260062678-A1 | CELL REPLACEMENT THERAPY FOR PULMONARY DISEASES | WNT3A, BMP4, GSK3B | ROCK2 14/4885ROCK1 12/4885PRKCD 68/4885 |
| US-12618830-B2 | Methods, culture medias and devices for generating embryos in vitro from stem cells | POU2F1, POU5F1, POU2F2 | ROCK2 2165/4885ROCK1 2793/4885PRKCD 677/4885 |
| US-20160177269-A1 | METHODS FOR GENERATING STEM CELL-DERIVED BETA CELLS AND METHODS OF USE THEREOF | IAPP, RNASE1, PNLIP | ROCK2 2425/4885ROCK1 2444/4885PRKCD 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.